{"schema_version":"secwatch.filing_event.v1","accession":"0001104659-23-114905","form_type":"8-K","ticker":"FENC","cik":"0001211583","company_name":"FENNEC PHARMACEUTICALS INC.","filed_at":"2023-11-07T23:59:59+00:00","discovered_at":"2026-05-14T18:03:28.443514+00:00","generated_at":"2026-06-08T13:38:48.334994+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Fennec Q3 2023: PEDMARK revenue $6.5M (+96% QoQ); UK approval for PEDMARQSI","bullets":["PEDMARK net product revenue $6.5M in Q3 2023, up 96% from $3.3M in Q2 2023.","Net loss narrowed to $1.9M ($0.07/share) from $8.1M ($0.31) in Q3 2022.","Received UK MHRA approval for PEDMARQSI in October 2023.","Cash and equivalents $12.4M at Sept 30, 2023; sufficient for at least 12 months.","Gross profit $6.2M; selling & marketing expenses $3.4M for U.S. and EU launch prep."],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-23-114905","json":"https://secwatch.observer/filing/0001104659-23-114905.json","markdown":"https://secwatch.observer/filing/0001104659-23-114905.md","text":"https://secwatch.observer/filing/0001104659-23-114905.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1211583/000110465923114905/0001104659-23-114905-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1211583/000110465923114905/tm2330040d1_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-08T13:38:48.334994+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"f0440710fe760a4b81bc26c7130d55eee2213adc","claim":"FENNEC PHARMACEUTICALS INC. reported the third quarter ended September 30, 2023 results: revenue $6.5 million, net income $1.9 million ($0.07 per share), EPS $0.07 per share.","evidence_excerpt":"EXHIBIT 99.1 Exhibit 99.1 FENNEC PHARMACEUTICALS ANNOUNCES THIRD QUARTER 2023 FINANCIAL RESULTS AND PROVIDES BUSINESS UPDATE ~ PEDMARK ® Net Product Revenue of $6.5 Million, a 96% Increase Compared to Second Quarter ~ ~ Strong Commercial Uptake Underscoring Significant Unmet Medical Need ~ ~ Received Approval in October 2023 by the Medicines and","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1211583/000110465923114905/0001104659-23-114905-index.htm","confidence":0.95,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the third quarter ended September 30, 2023"},{"label":"Revenue","value":"$6.5 million"},{"label":"Net income","value":"$1.9 million ($0.07 per share)"},{"label":"EPS","value":"$0.07 per share"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}